Many pharmaceutical companies have tried to find an effective treatment for Alzheimer's disease, which affects approximately 55 million people worldwide and is increasing day by day, but they have not been successful.

The latest work on Alzheimer's treatment will be a beacon of hope for countless people.

Effective in the Early Stage of Alzheimer's

An experimental Alzheimer's drug developed by Eisai Co Ltd (4523.T) and Biogen (BIIB.O) slowed cognitive and functional decline in a trial with multiple patients in the early stages of the disease.

"It's not a huge impact, it's a positive impact," said Ronald Petersen, director of the Mayo Clinic Alzheimer's Research Center, when speaking of the Eisai-Biogen drug trial results.

Slows Alzheimer's Progression

The drug slowed disease progression by 27 percent compared to placebo, meeting the study's main goal, and potentially giving patients and their families hopelessness for an effective treatment.

Despite the race to stop Alzheimer's from progressing, the number of Americans living with the disease is expected to nearly double by 2050, reaching 13 million, according to the Alzheimer's Association.

Globally, this figure is estimated to reach 139 million by 2050 without effective treatment.